See more : Jyske Invest Korte Obligationer KL (JYIKOB.CO) Income Statement Analysis – Financial Results
Complete financial analysis of SOPHiA GENETICS SA (SOPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SOPHiA GENETICS SA, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Chibougamau Independent Mines Inc. (CMAUF) Income Statement Analysis – Financial Results
- Early Age Co., Ltd. (3248.T) Income Statement Analysis – Financial Results
- Index Oil and Gas Inc. (IXOG) Income Statement Analysis – Financial Results
- Santander Bank Polska S.A. (SPL.WA) Income Statement Analysis – Financial Results
- Founder’s Consultants Holdings Inc. (6542.T) Income Statement Analysis – Financial Results
SOPHiA GENETICS SA (SOPH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.sophiagenetics.com
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 62.37M | 47.56M | 40.45M | 28.40M | 25.36M |
| Cost of Revenue | 19.46M | 16.31M | 15.23M | 10.71M | 7.53M |
| Gross Profit | 42.91M | 31.25M | 25.22M | 17.69M | 17.83M |
| Gross Profit Ratio | 68.80% | 65.71% | 62.35% | 62.29% | 70.30% |
| Research & Development | 36.97M | 35.37M | 26.58M | 18.59M | 15.02M |
| General & Administrative | 53.30M | 55.82M | 41.51M | 18.97M | 15.67M |
| Selling & Marketing | 28.42M | 28.27M | 28.74M | 17.43M | 19.41M |
| SG&A | 81.72M | 84.08M | 70.24M | 36.40M | 35.08M |
| Other Expenses | -954.00K | -377.00K | -108.00K | -129.00K | 16.00K |
| Operating Expenses | 117.74M | 119.08M | 96.71M | 54.86M | 50.12M |
| Cost & Expenses | 137.20M | 135.38M | 111.94M | 65.57M | 57.65M |
| Interest Income | 4.55M | 1.32M | 20.00K | 96.00K | 86.00K |
| Interest Expense | 588.00K | 639.00K | 658.00K | 840.00K | 976.00K |
| Depreciation & Amortization | 8.34M | 5.57M | 3.61M | 2.39M | 1.91M |
| EBITDA | -70.70M | -82.67M | -70.84M | -38.76M | -30.74M |
| EBITDA Ratio | -113.35% | -172.94% | -167.76% | -122.11% | -119.42% |
| Operating Income | -74.83M | -87.82M | -71.49M | -37.17M | -32.29M |
| Operating Income Ratio | -119.97% | -184.66% | -176.73% | -130.86% | -127.30% |
| Total Other Income/Expenses | -3.67M | 238.00K | -2.02M | -3.84M | -1.34M |
| Income Before Tax | -78.50M | -87.59M | -73.51M | -41.23M | -33.63M |
| Income Before Tax Ratio | -125.85% | -184.16% | -181.72% | -145.16% | -132.60% |
| Income Tax Expense | 486.00K | -136.00K | 168.00K | -1.89M | 162.00K |
| Net Income | -78.98M | -87.45M | -73.68M | -39.34M | -33.79M |
| Net Income Ratio | -126.63% | -183.87% | -182.14% | -138.52% | -133.23% |
| EPS | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| EPS Diluted | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| Weighted Avg Shares Out | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
| Weighted Avg Shares Out (Dil) | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024
New generation of SOPHiA DDM TM integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers BOSTON and ROLLE, Switzerland , Sept. 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company...
SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference
BOSTON and ROLLE, Switzerland , Aug. 28, 2024 /PRNewswire/ -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Morgan Stanley Healthcare Conference and the 9th Annual TD Cowen FutureHealth...
SOPHiA DDM™ Platform Certified Under IVDR
Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland , Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that its...
SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for SOPHiA GENETICS (SOPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
SOPHiA GENETICS Reports Second Quarter 2024 Results
Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management B uffers Loss BOSTON and ROLLE, Switzerland , Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine,...
SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™
The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in...
SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that...
SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today...
Source: https://incomestatements.info
Category: Stock Reports